Search company, investor...

Minaris Regenerative Medicine

rm.minaris.com

Stage

Acquired | Acquired

About Minaris Regenerative Medicine

Minaris Regenerative Medicine, fka Progenitor Cell Therapy (PCT), provides a platform for cell therapy CDMO services at cGMP standards - including clinical manufacturing, commercial manufacturing, and manufacturing development.

Headquarters Location

4 Pearl Ct.

Allendale, New Jersey, 07401,

United States

Missing: Minaris Regenerative Medicine's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Minaris Regenerative Medicine's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Minaris Regenerative Medicine

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Minaris Regenerative Medicine is included in 1 Expert Collection, including Regenerative Medicine.

R

Regenerative Medicine

1,818 items

Regenerative medicine refers to the process of activating, replacing, engineering or regenerating human genetic material, cells, tissues or organs to restore normal function. It also includes bioengineered tissues used for in vitro testing (e.g. organ-on-a-chip, organoids).

Latest Minaris Regenerative Medicine News

Cellusion and Minaris Regenerative Medicine Enter Alliance for the Manufacturing of Corneal Endothelial Cell Regenerative Therapy

Oct 25, 2022

Cellusion, a Japanese regenerative medicine startup aiming to solve the global corneal transplant waiting list problem, and Minaris Regenerative Medicine, a global contract and development manufacturing organization, announced a Letter of Intent (LOI) of the Manufacturing of CLS001 for a corneal endothelial cell regenerative therapy in the United States. Financial terms of the deal were not disclosed.  Under the LOI, Cellusion and Minaris will develop the manufacturing process of Cellusion’s leading program, CLS001, a novel regenerative medicine product for bullous keratopathy treatment. Minaris’ Allendale, New Jersey team will perform process optimization to meet requirements from the FDA. “We are very enthusiastic to have the partnership with Minaris, a well-established regenerative medicine partner with over 20 years experiences including the predecessor companies, Progenitor Cell Therapy and Hitachi Chemical, and one of the leading CDMOs in the U.S. since the dawn of the field,” Shin Hatou, MD, PhD, CEO of Cellusion, said in a company news release. “Together, we make our best efforts to develop the robust manufacturing process of CLS001 for patients suffering from bullous keratopathy due to the cornea donor shortage all over the world.” Hiroto Bando, PhD, MBA, CEO of Minaris said, “It is exciting for Minaris Regenerative Medicine to be part of advancing a potential solution to corneal blindness, a widespread need, and we look forward to leveraging our extensive development resources to support Cellusion. We hope to position Cellusion well for its next clinical trial and potentially further support them in their manufacturing needs.” According to the World Health Organization (WHO) report, in 2021, at least 1 billion near or distant vision impairment cases could have been prevented or has yet to be addressed globally. Blindness of the cornea is the fourth leading cause of blindness, and is one of the major causes of visual deficiency after cataract, glaucoma, and age-related macular degeneration. Most of the patients with corneal blindness need corneal transplantation to restore their sight, but only 180,000 corneal transplants are conducted every year due to severe donor cornea shortage issues. Cellusion is striving to solve this problem, and by doing so support the UN’s Sustainable Development Goals 3 to ensure healthy lives and promote well-being for all ages. Cellusion has announced that patient recruitment began for an investigator-initiated, first-in-human study of CLS001 at the Keio University Hospital. Cellusion has been preparing to start its clinical trial in Japan within a few years followed by global studies in the US and EU region.

Minaris Regenerative Medicine Frequently Asked Questions (FAQ)

  • Where is Minaris Regenerative Medicine's headquarters?

    Minaris Regenerative Medicine's headquarters is located at 4 Pearl Ct., Allendale.

  • What is Minaris Regenerative Medicine's latest funding round?

    Minaris Regenerative Medicine's latest funding round is Acquired.

  • Who are the investors of Minaris Regenerative Medicine?

    Investors of Minaris Regenerative Medicine include Caladrius Biosciences.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.